TY - JOUR KW - rSPV KW - SS2 KW - truncated MRP KW - mice KW - immunogenicity KW - protective efficacy AU - D Huang AU - H Zhu AU - H Lin AU - J Xu AU - C Lu AB - To explore the potential of the swinepox virus (SPV) as vector for Streptococcussuis vaccines, a vector system was developed for the construction of a recombinantSPV carrying bacterial genes. Using this system, a recombinant virusexpressing ... BT - Berliner und Münchener Tierärztliche Wochenschrift C1 - {"oldId":70167,"title":"First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice","topline":"","teaserText":"To explore the potential of the swinepox virus (SPV) as vector for Streptococcussuis vaccines, a vector system was developed for the construction of a recombinantSPV carrying bacterial genes. Using this system, a recombinant virusexpressing ...","content":"

Summary<\/span>
To explore the potential of the swinepox virus (SPV) as vector for Streptococcus suis vaccines, a vector system was developed for the construction of a recombinant SPV carrying bacterial genes. Using this system, a recombinant virus expressing truncated muramidase-released protein (MRP) of S. suis type 2 (SS2), designated rSPV-MRP, was produced and identified by PCR, western blotting and immunofluorescence assays. The rSPV-MRP was found to be only slightly attenuated in PK-15 cells, when compared with the wild-type virus. After immunization intramuscularly with rSPV-MRP, SS2 inactive vaccine (positive control), wild-type SPV (negative control) and PBS (blank control) respectively, all CD1 mice were challenged with a lethal dose or a sublethal dose of SS2 highly virulent strain ZY05719. While SS2 inactive vaccine protected all mice, immunization with rSPV-MRP resulted in 60% survival and protected mice against a lethal dose of the highly virulent SS2 strain, compared with the negative control (P S. suis vaccines for the use in pigs has to be evaluated in further studies.

Keywords:<\/span>
rSPV, SS2, truncated MRP, mice, immunogenicity, protective efficacy


Zusammenfassung<\/span>
Um das Potenzial des Schweinepockenvirus (SPV) als Vektor f\u00fcr eine Streptococcus suis-Vakzine zu untersuchen, wurde ein Vektorsystem f\u00fcr rekombinante bakterielle Gene tragende SPV konstruiert. Mittels dieses Systems gelang die Expression des verk\u00fcrzten Muramidase-released Proteins (MRP) von S. suis Typ 2 (SS2) durch das rekombinante Virus rSPV-MRSP. Dies wurde mittels PCR, Western Blotting und Immunfluoreszenz-Test belegt. Im Vergleich zum Wildtypvirus war rSVP-MRP in PK-15 Zellen nur geringf\u00fcgig attenuiert. Nach intramuskul\u00e4rer Immunisierung mit rSPV-MRP, einer inaktivierten SS2-Vakzine (Positiv-Kontrolle), Wildtypvirus SPV (Negativ-Kontrolle) oder PBS (Blank-Kontrolle) wurden alle CD1-M\u00e4use mit einer letalen oder subletalen Dosis des hochvirulenten SS2-Stammes ZY05719 infiziert. W\u00e4hrend die inaktivierte SS2-Vakzine alle M\u00e4use sch\u00fctzte, f\u00fchrte die rSPV-MRSP-Vakzine zu einer 60%igen \u00dcberlebensrate und sch\u00fctzte die M\u00e4use, verglichen mit der Negativ-Kontrolle, signifikant (P S. suis-Vakzinen im Schwein eingesetzt werden k\u00f6nnen, muss in zuk\u00fcnftigen Studien untersucht werden.

Schl\u00fcsselw\u00f6rter:<\/span>
rSPV, SS2, verk\u00fcrztes MRP, Maus, Immunogenit\u00e4t, Schutz<\/p>","categories":["Tier\u00e4rztliche Wochenschrift","Abostufe BMTW","Fachartikel"],"fromDate":"Mar 12, 2012 12:00:00 AM","toDate":"Dec 31, 2050 12:00:00 AM","oldUrls":["http:\/\/vetline.de\/rspv-ss2-truncated-mrp-mice-immunogenicity-protective-efficacy\/150\/3130\/70167"],"doiLanguage":"englisch","doiProductFormat":"Online","doiPublisher":"Schl\u00fctersche Verlagsgesellschaft mbH & Co. KG","doiSerialWorkTitle":"Berl. M\u00fcnch. Tier\u00e4rztl. Wschr.","doiDocumentUri":"http:\/\/www.vetline.de\/rspv-ss2-truncated-mrp-mice-immunogenicity-protective-efficacy\/150\/3130\/70167","doiSource":"Berl. M\u00fcnch. Tier\u00e4rztl. Wschr. 125: 3-4, 144-152 (2012)","doiissn":"0005-9366","doiNr":"10.2376\/0005-9366-125-144","doiFirstPage":"144","doiLastPage":"152","doiTransmitted":true,"doiAuthor":"Huang D, Zhu H, Lin H, Xu J, Lu C","pdf":{"path":"http:\/\/data\/bmtw_2012_03_0144.pdf","title":"bmtw_2012_03_0144.pdf","description":"First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice

"},"authors":[{"firstName":"D","middleName":"","lastName":"Huang"},{"firstName":"H","middleName":"","lastName":"Zhu"},{"firstName":"H","middleName":"","lastName":"Lin"},{"firstName":"J","middleName":"","lastName":"Xu"},{"firstName":"C","middleName":"","lastName":"Lu"}],"contentOptimised":"

Summary<\/strong>
To explore the potential of the swinepox virus (SPV) as vector for Streptococcus suis vaccines, a vector system was developed for the construction of a recombinant SPV carrying bacterial genes. Using this system, a recombinant virus expressing truncated muramidase-released protein (MRP) of S. suis type 2 (SS2), designated rSPV-MRP, was produced and identified by PCR, western blotting and immunofluorescence assays. The rSPV-MRP was found to be only slightly attenuated in PK-15 cells, when compared with the wild-type virus. After immunization intramuscularly with rSPV-MRP, SS2 inactive vaccine (positive control), wild-type SPV (negative control) and PBS (blank control) respectively, all CD1 mice were challenged with a lethal dose or a sublethal dose of SS2 highly virulent strain ZY05719. While SS2 inactive vaccine protected all mice, immunization with rSPV-MRP resulted in 60% survival and protected mice against a lethal dose of the highly virulent SS2 strain, compared with the negative control (P S. suis vaccines for the use in pigs has to be evaluated in further studies.

Keywords:<\/strong>
rSPV, SS2, truncated MRP, mice, immunogenicity, protective efficacy


Zusammenfassung<\/strong>
Um das Potenzial des Schweinepockenvirus (SPV) als Vektor f\u00fcr eine Streptococcus suis-Vakzine zu untersuchen, wurde ein Vektorsystem f\u00fcr rekombinante bakterielle Gene tragende SPV konstruiert. Mittels dieses Systems gelang die Expression des verk\u00fcrzten Muramidase-released Proteins (MRP) von S. suis Typ 2 (SS2) durch das rekombinante Virus rSPV-MRSP. Dies wurde mittels PCR, Western Blotting und Immunfluoreszenz-Test belegt. Im Vergleich zum Wildtypvirus war rSVP-MRP in PK-15 Zellen nur geringf\u00fcgig attenuiert. Nach intramuskul\u00e4rer Immunisierung mit rSPV-MRP, einer inaktivierten SS2-Vakzine (Positiv-Kontrolle), Wildtypvirus SPV (Negativ-Kontrolle) oder PBS (Blank-Kontrolle) wurden alle CD1-M\u00e4use mit einer letalen oder subletalen Dosis des hochvirulenten SS2-Stammes ZY05719 infiziert. W\u00e4hrend die inaktivierte SS2-Vakzine alle M\u00e4use sch\u00fctzte, f\u00fchrte die rSPV-MRSP-Vakzine zu einer 60%igen \u00dcberlebensrate und sch\u00fctzte die M\u00e4use, verglichen mit der Negativ-Kontrolle, signifikant (P S. suis-Vakzinen im Schwein eingesetzt werden k\u00f6nnen, muss in zuk\u00fcnftigen Studien untersucht werden.

Schl\u00fcsselw\u00f6rter:<\/strong>
rSPV, SS2, verk\u00fcrztes MRP, Maus, Immunogenit\u00e4t, Schutz<\/p>","primaryLanguage":"englisch","summary":"To explore the potential of the swinepox virus (SPV) as vector for Streptococcus suis vaccines, a vector system was developed for the construction of a recombinant SPV carrying bacterial genes. Using this system, a recombinant virus expressing truncated muramidase-released protein (MRP) of S. suis type 2 (SS2), designated rSPV-MRP, was produced and identified by PCR, western blotting and immunofluorescence assays. The rSPV-MRP was found to be only slightly attenuated in PK-15 cells, when compared with the wild-type virus. After immunization intramuscularly with rSPV-MRP, SS2 inactive vaccine (positive control), wild-type SPV (negative control) and PBS (blank control) respectively, all CD1 mice were challenged with a lethal dose or a sublethal dose of SS2 highly virulent strain ZY05719. While SS2 inactive vaccine protected all mice, immunization with rSPV-MRP resulted in 60% survival and protected mice against a lethal dose of the highly virulent SS2 strain, compared with the negative control (P S. suis vaccines for the use in pigs has to be evaluated in further studies.","keywords":["rSPV","SS2","truncated MRP","mice","immunogenicity","protective efficacy"],"zusammenfassung":"Um das Potenzial des Schweinepockenvirus (SPV) als Vektor f\u00fcr eine Streptococcus suis-Vakzine zu untersuchen, wurde ein Vektorsystem f\u00fcr rekombinante bakterielle Gene tragende SPV konstruiert. Mittels dieses Systems gelang die Expression des verk\u00fcrzten Muramidase-released Proteins (MRP) von S. suis Typ 2 (SS2) durch das rekombinante Virus rSPV-MRSP. Dies wurde mittels PCR, Western Blotting und Immunfluoreszenz-Test belegt. Im Vergleich zum Wildtypvirus war rSVP-MRP in PK-15 Zellen nur geringf\u00fcgig attenuiert. Nach intramuskul\u00e4rer Immunisierung mit rSPV-MRP, einer inaktivierten SS2-Vakzine (Positiv-Kontrolle), Wildtypvirus SPV (Negativ-Kontrolle) oder PBS (Blank-Kontrolle) wurden alle CD1-M\u00e4use mit einer letalen oder subletalen Dosis des hochvirulenten SS2-Stammes ZY05719 infiziert. W\u00e4hrend die inaktivierte SS2-Vakzine alle M\u00e4use sch\u00fctzte, f\u00fchrte die rSPV-MRSP-Vakzine zu einer 60%igen \u00dcberlebensrate und sch\u00fctzte die M\u00e4use, verglichen mit der Negativ-Kontrolle, signifikant (P S. suis-Vakzinen im Schwein eingesetzt werden k\u00f6nnen, muss in zuk\u00fcnftigen Studien untersucht werden.","schluesselwoerter":["rSPV","SS2","verk\u00fcrztes MRP","Maus","Immunogenit\u00e4t","Schutz"],"translatedTitle":"","abstractE":"To explore the potential of the swinepox virus (SPV) as vector for Streptococcussuis vaccines, a vector system was developed for the construction of a recombinantSPV carrying bacterial genes. Using this system, a recombinant virusexpressing ...","date":{"year":2012,"date":"03\/2012","accepted":"2012-03-12"},"volume":"125","openAccess":false,"journal":"Berliner und M\u00fcnchener Tier\u00e4rztliche Wochenschrift","titleImageId":944,"pages":"144-152","redirects":["rspv-ss2-truncated-mrp-mice-immunogenicity-protective-efficacy\/150\/3130\/70167"],"tierartCategories":[],"artikelartCategories":["Tier\u00e4rztliche Wochenschrift","Abostufe BMTW","Fachartikel"]} CY - Hannover DA - 03/2012 DO - 10.2376/0005-9366-125-144 LA - English N2 - To explore the potential of the swinepox virus (SPV) as vector for Streptococcussuis vaccines, a vector system was developed for the construction of a recombinantSPV carrying bacterial genes. Using this system, a recombinant virusexpressing ... PB - Schlütersche Verlagsgesellschaft mbH & Co. KG PP - Hannover PY - 2012 SP - 144 EP - 152 T1 - First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice T2 - Berliner und Münchener Tierärztliche Wochenschrift TI - First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice VL - 125 SN - 0005-9366 ER -